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No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer Sir Chromosome region 1 lq22-23 is a site of frequent loss of heterozygosity (LOH) in breast cancer (Hampton et al, 1994a) , ovarian cancer (Davis et al, 1996) and other malignancies (Keldysh et al, 1993; Hampton et al, 1994b; Herbst et al, 1995) , suggesting the presence of an important tumour-suppressor gene(s) (TSG) . The most obvious candidate in the region, the gene responsible for ataxia telangiectasia, has recently been ruled out as the target of these deletions in breast cancer (Vorechovsky et al, 1996) . The human progesterone receptor (PR) gene is also located in this region (Rousseau-Merck et al, 1987) , and there is evidence that it may have tumour-suppressing properties. For example, in ovarian cancer, LOH at the PR locus is associated with reduced PR protein levels (Gabra et al, 1995a ) and with adverse clinicopathological features (Gabra et al, 1995b) . Furthermore, there is an association between PR levels and histological subtypes of ovarian cancer (Vierikko et al, 1983) . In particular, endometrioid tumours contain elevated PR levels relative to other histological subtypes (Slotman et al, 1990 ). In breast cancer, similar relationships between PR expression and tumour behaviour (Stierer et al, 1993) and PR expression and llq LOH (Magdelenat et al, 1994) (lanes 1, 2, 3, 5, 6, 7, 8) , heterozygotes for the PROGINS insertion (lanes 9 and 10) and a homozygote for the PROGINS insertion (lane 4) are shown been documented. These observations are consistent with a tumour-suppressive role for PR and suggest that it is the target of the Ilq22-23 LOH.
In the context of these studies, common polymorphisms of the PR gene that may encode aberrant forms of the PR have been investigated for their association with breast and ovarian cancers. One such polymorphism, designated PROGINS, consists of a 306-bp insertion of the PV/HS-l Alu subfamily in intron G of the PR gene . Rowe et al speculated that this insertion might result in expression of an aberrant splice form of PR with altered ligand and hormone-binding properties, since it introduces a consensus splice acceptor site just downstream of a consensus splice donor site. An increased frequency of the PROGINS allele (T2) has been reported in patients with ovarian cancer and breast cancer (Garrett et al, 1995) . However, the association with ovarian cancer was based on a total of only 67 cases, 26 from Germany and 41 from Ireland . In the breast cancer study, the frequency of the PROGINS allele among 187 cases was increased compared with the 90 controls but did not reach statistical significance (Garrett et al, 1995) .
We assessed the frequency of the PROGINS allele in the genomic DNA from 231 sporadic ovarian cancer cases, 292 breast cancer cases and a control group of 220 healthy volunteers in a region of southern England. Previous Polymerase chain reaction (PCR) analyses of the distribution of the TI and T2 allele used primers that flank regions of 3.0 kb (T2) and 2.7 kb (TI) , which were inherently difficult to amplify and resolve on agarose gels. We developed a new set of primers that produce products of 455 bp (T2) and 149 bp (TI), which were amenable to amplification and easily resolved on 1.5% mini agarose gels, as shown in Figure 1 . The distribution of the TI and T2 alleles in the breast cancer, ovarian cancer and non-cancer control groups are shown in Table 1 . No significant differences could be demonstrated in the distribution of the alleles between the control group and the ovarian (P = 0.86) or breast cancer (P = 0.73) groups. The observed frequency distribution of the alleles TI and T2 were compared with the expected allele frequency distribution according to the Hardy-Weinberg equation, and X2 analysis revealed no significant differences, with the ovarian cancer, breast cancer and control groups all following the expected distributions. The frequency of the T1/T2 heterozygotes in our control group (24.5%) was similar to that observed in previous studies of an Irish population (25.5%) but was significantly higher than that found in a German population (12%) . Our finding that there is no significant difference between the frequency of the PROGINS allele in patients with ovarian cancer and the noncancer control group is at variance with the findings of McKenna et al. They based the association with ovarian cancer on a study of 41 cancer patients and 83 control subjects from Ireland and 26 cancer patients and 101 control subjects from Germany . An over-representation of the Tl/T2 heterozygote was demonstrated among the pooled Irish and German cancer groups (35%) compared with the pooled controls groups (18%). However, when analysed separately neither the Irish nor German cancer groups could be demonstrated to differ significantly from the corresponding control groups. In fact, the only reason the pooled results reached statistical significance was that the frequency of the T2 allele in the German control group was very low (0.07 compared with the Irish control group frequency of 0.17).
To investigate further the potential cancer predisposing influence of the PROGINS allele, we analysed for LOH in the ovarian cancer cases by assessing the PCR products obtained from peripheral blood leucocyte DNA and tumour DNA for allelotype loss. We reasoned that, if PROGINS represents a defective copy of the PR gene, then according to the two-hit hypothesis of Knudson (1971) , LOH at this locus should remove the wild-type allele. Matching tumour DNA was available for 11 of the 52 ovarian tumours that were heterozygous for the PROGINS allele. LOH was detected in four of the 11 cases and in each instance it was the PROGINS allele that was deleted. This finding is consistent with the absence of an association of PROGINS with the cancer groups and supports our view that PROGINS has no functional significance with respect to cancer predisposition.
Despite this lack of association, the PR gene remains a good candidate for the target of the 1 lq22-23 LOH. Our finding of 36% LOH at this locus in ovarian cancer together with the work of Gabra et al (1995a, b) 
